Dihydrofolate Reductase Antikörper (Cy7)
Kurzübersicht für Dihydrofolate Reductase Antikörper (Cy7) (ABIN1418462)
Target
Alle Dihydrofolate Reductase (DHFR) Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
-
-
Aufreinigung
- purified by Protein A
-
Immunogen
- KLH conjugated synthetic peptide derived from human DHFR
-
Isotyp
- IgG
-
-
-
-
Kommentare
-
Excitation / Emission wavelength: 743nm / 767nm
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Liquid
-
Konzentration
- 1 µg/µL
-
Buffer
- Aqueous buffered solution containing 100 µg/mL BSA, 50 % glycerol and 0.09 % sodium azide.
-
Konservierungsmittel
- Sodium azide
-
Vorsichtsmaßnahmen
- This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Lagerung
- 4 °C
-
Informationen zur Lagerung
- Store at 4 °C for 12 months
-
Haltbarkeit
- 12 months
-
-
- Dihydrofolate Reductase (DHFR)
-
Andere Bezeichnung
- DHFR
-
Hintergrund
- DHFR catalyzes the NADPH-dependent reduction of dihydrofolate to tetrahydrofolate, and is a crucial enzyme for the synthesis of purines, pyrimidines and some amino acids. Inhibition of the activity of this enzyme leads to arrest of DNA synthesis and cell death. Gene expression of methotrexate (MTX)-resistant variants of DHFR in normal hematopoietic cells is a potential strategy to permit administration of larger doses of MTX by alleviating drug toxicity in normal cells and tissues that are drug sensitive.
-
Molekulargewicht
- 21kDa
-
Gen-ID
- 1719
-
HGNC
- 0
-
Pathways
- Mitotic G1-G1/S Phases
Target
-